1. Thirty moderately severely hypertensive patients were studied in a double-blind comparison of minoxidil and hydrallazine in combination with frusemide and propranolol.
Introduction
Minoxidil, a piperidino-pyrimidine derivative (Upjohn U-10,858), is an oral vasodilator affecting vascular smooth muscle, which is still under investigation. A previous study documented its usefulness in accelerated hypertension refractory to conventional medication (Wilburn, Blaufuss & Bennett, 1975) . A double-blind comparison of minoxidil and hydrallazine,carried out o n a population of thirty moderately severely hypertensive patients, is the subject of the present study. The protocol called for following patients for a period of up to 30 weeks, but many patients were followed thereafter for up to 1 year.
Methods
All thirty patients were initially examined physically and given chest X-ray, electrocardiogram and routine laboratory tests. After informed consent was obtained for using an investigational drug, as well as doses of propranolol which were greater than standard, patients were taken off all medications for a 'wash-out' period of 2-17 days. Frusemide and propranolol were then given for up to 3 weeks. If diastolic blood pressure was greater than 104 mmHg, the patient was then randomly started on 2-5 mg of minoxidil or 25 mg of hydralazine/day. The patients were seen at weekly intervals and dosages of vasodilator drugs were tritrated upwards over a period of 6-10 weeks to acceptable blood pressure readings ( < 140/90 mmHg) or maximal dosage (40 mg of minoxidil/day or 400 mg of hydrallazine/day). After initiation of minoxidil or hydrallazine, the patients were seen weekly for 34 months, at least monthly for an additional 2 months and then at least bimonthly through 1 year. The double-blind aspect of the study was ended at 30 weeks. At each clinic visit the blood pressure and pulse rate, weight, patient's assessment of well-being and results of physical examination were recorded. Chest X-ray and electrocardiogram, routine laboratory tests, were obtained on a monthly basis for 34 months and then bimonthly for the remainder of the year. In the ECG the presence or absence of RS voltage criteria for left ventricular hypertrophy (LVH) was recorded; in the chest X-rays the cardiothoracic ratios (CT) were recorded. Echocardiography (Smith-Kline Echoline 20 Echoscope) was obtained within 6 months of initiation of minoxidil or hydrallazine in twenty-four patients; eighteen of these had two or more echocardiograms. There were thirty patients, age range 29-66 years. Average age on minoxidil was 43 and on hydrallazine 46 years. There were twenty-one blacks (ten on minoxidil, eleven on hydrallazine) and nine whites; nineteen males and eleven females. Twelve of the thirty were known t o have hypertension for more than 10 years. All thirty had essential hypertension.
Plasma catecholamines were measured in fourteen

Results and discussion
Numbers in study
Results are summarized in Table 1 . One patient on minoxidil died of a stroke a t 2 weeks, with severe high blood pressure; one patient who was started on chronic haemodialysis at 1 month discontinued the study a t 10 months; four patients on minoxidil discontinued the study of their own volition (three moved from the area, one had work conflicting with clinic appointments). One patient on hydrallazine had a hypertensive reaction with severe tachycardia at 2 weeks and discontinued study. Of the thirty patients who started on the double-blind protocol, twenty-four completed at least 54 months of study, nineteen completed a t least 1 year and twenty-three are still being followed. Two patients initially on hydrallazine were switched to minoxidil at 14-16 weeks after breaking the code because of poor blood pressure control.
Blood pressures and therapeutic regimen
In the pre-study phase, blood pressures and evidence of end-organ damage (retinopathy, cardiac enlargement and renal function) were similar in Phases: a, pre-study phase; b, 22 weeks; c, 52 weeks. LVH = left ventricular hypertrophy. ** Difference is significant (P < 0.005).
Phase
Minoxidil Hydrallazine Vasodilator drugs in severe hypertension 595s both groups. At 22 weeks the blood pressures in the two groups were adequately controlled and were similar. However, of the nineteen patients followed for at least 1 year, the difference in blood pressures between the two groups is larger: 129 f 171 78 f 8 mmHg for the minoxidil group and 137 k 131 91 f 10 mmHg for the hydrallazine group. The difference in the diastolic blood pressure is significant (P <0.005). At 1 year only two of nine patients were on the maximal dosage of 40 mg of minoxidil/day, whereas seven of ten patients were on the maximal dose of 400 mg of hydrallazine1day. No changes were observed in liver function, blood glucose, erythrocyte or leucocyte counts or haemoglobin, and no patient developed anti-nuclear antibodies.
Renal function
Serum creatinine in the pre-study phase was similar in each group, with nine of the fifteen minoxidil patients and eight of the fifteen hydrallazine patients being above the normal of 1.2 mg/100 ml. At 1 year there was little difference between the two groups. However, one of the minoxidil patients went on to chronic haemodialysis at 1 month and his creatinine is not included in the tabulations.
Evidence of cardiomegaly
In the pre-study phase, a majority of patients in both groups had at least the minimal voltage requirement for left ventricular hypertrophy. Despite good to excellent control of blood pressure, this had not completely resolved in all patients after 1 year. In those echocardiograms in which it could be measured, the ejection fractions initially were high and tended to remain the same or increase in both groups despite the large doses of propranolol. In one patient in each group the initial and final ejection fractions were below the normal of > 55%; these values are not included in the averages. The values for left ventricular wall and septa1 thickness were similar for both groups initially and finally, approximating to the upper limit of normal (1.2 cm). There were small pericardial effusions in three of the minoxidil patients and one of the hydrallazine patients, but all four patients were asymptomatic. Sodium and fluid retention was common in both groups but was readily controlled by frusemide. In patients with peripheral oedema, no elevation of venous pressure or rlles were noted.
The average cardiothoracic ratios for each group were similar, and did not change over a period of 1 year.
Plasma catecholamines were moderately elevated (1 5-2 times normal) in each group and were similar.
Patient acceptance of both drugs was excellent. Almost all of the minoxidil patients developed mild hirsutism but no one discontinued the drug because of this side effect. At the end of the initial 22 weeks period, twenty-nine of the thirty patients were judged to be employable in their usual occupation.
